[go: up one dir, main page]

NO20005162L - Forbindelser som inhiberer bindingen av integriner til deres reseptorer - Google Patents

Forbindelser som inhiberer bindingen av integriner til deres reseptorer

Info

Publication number
NO20005162L
NO20005162L NO20005162A NO20005162A NO20005162L NO 20005162 L NO20005162 L NO 20005162L NO 20005162 A NO20005162 A NO 20005162A NO 20005162 A NO20005162 A NO 20005162A NO 20005162 L NO20005162 L NO 20005162L
Authority
NO
Norway
Prior art keywords
compounds
binding
receptors
inhibit
integrins
Prior art date
Application number
NO20005162A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005162D0 (no
Inventor
Ian L Scott
Bore G Raju
Ronald J Biediger
Vanessa O Grabbe
Jamal M Kassir
Karin M Keller
Shuqun Lin
Robert V Market
Timothy P Kogan
Original Assignee
Texas Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Biotechnology Corp filed Critical Texas Biotechnology Corp
Publication of NO20005162D0 publication Critical patent/NO20005162D0/no
Publication of NO20005162L publication Critical patent/NO20005162L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
NO20005162A 1998-04-16 2000-10-13 Forbindelser som inhiberer bindingen av integriner til deres reseptorer NO20005162L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8201998P 1998-04-16 1998-04-16
PCT/US1999/008305 WO1999052493A2 (en) 1998-04-16 1999-04-15 Compounds that inhibit the binding of integrins to their receptors

Publications (2)

Publication Number Publication Date
NO20005162D0 NO20005162D0 (no) 2000-10-13
NO20005162L true NO20005162L (no) 2000-12-15

Family

ID=22168519

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20005162A NO20005162L (no) 1998-04-16 2000-10-13 Forbindelser som inhiberer bindingen av integriner til deres reseptorer
NO20005161A NO20005161L (no) 1998-04-16 2000-10-13 N,N-disubstituerte amider som inhiberer bindingen av integriner til deres reseptorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20005161A NO20005161L (no) 1998-04-16 2000-10-13 N,N-disubstituerte amider som inhiberer bindingen av integriner til deres reseptorer

Country Status (20)

Country Link
US (3) US6096773A (pt)
EP (2) EP1079825B1 (pt)
JP (2) JP4949552B2 (pt)
KR (2) KR20010042704A (pt)
CN (2) CN1311676A (pt)
AT (2) ATE402170T1 (pt)
AU (2) AU3748399A (pt)
BR (2) BR9909626A (pt)
CA (2) CA2328990C (pt)
DE (2) DE69942610D1 (pt)
ES (2) ES2345471T3 (pt)
HU (2) HUP0101419A3 (pt)
ID (1) ID28658A (pt)
IL (2) IL138973A0 (pt)
NO (2) NO20005162L (pt)
NZ (1) NZ507534A (pt)
PL (2) PL343770A1 (pt)
SK (2) SK15592000A3 (pt)
TR (2) TR200100141T2 (pt)
WO (2) WO1999052493A2 (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
EP1079825B1 (en) 1998-04-16 2010-07-21 Encysive Pharmaceuticals, Inc Compounds that inhibit the binding of integrins to their receptors
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) * 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
CN1231212C (zh) 1999-01-22 2005-12-14 依兰制药公司 抑制vla－4介导的白细胞粘着的多环化合物
TW593284B (en) 1999-01-22 2004-06-21 Elan Pharm Inc Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
IL143929A0 (en) 1999-01-22 2002-04-21 Elan Pharm Inc Acyl derivatives which treat vla-4 related disorders
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
CA2361162A1 (en) 1999-03-01 2000-09-08 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7-receptor antagonists
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6972296B2 (en) * 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6420418B1 (en) 1999-08-16 2002-07-16 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
AU2018301A (en) 1999-12-28 2001-07-24 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
US20040018192A1 (en) * 2000-02-03 2004-01-29 Toshiaki Wakabayashi Integrin expression inhibitors
US7098215B2 (en) * 2000-04-14 2006-08-29 Kureha Chemical Industry Co., Ltd. Nitrogenous compounds and antiviral drugs containing the same
EP1332132B1 (en) 2000-04-17 2007-10-10 UCB Pharma, S.A. Enamine derivatives as cell adhesion molecules
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
JP2004505110A (ja) 2000-08-02 2004-02-19 セルテック　アール　アンド　ディ　リミテッド ３位置換イソキノリン−１−イル誘導体
DE10063173A1 (de) 2000-12-18 2002-06-20 Merck Patent Gmbh Harnstoff- und Urethanderivate
JPWO2002094261A1 (ja) * 2001-05-24 2004-09-02 呉羽化学工業株式会社 含窒素化合物からなるｃｘｃｒ４拮抗作用を有する薬剤
JP2004536071A (ja) * 2001-05-25 2004-12-02 クイーンズ　ユニバーシティ　アット　キングストン 複素環ベータアミノ酸およびそれらの抗癲癇誘発剤としての使用
EP1431290A4 (en) * 2001-09-28 2004-12-15 Kureha Chemical Ind Co Ltd NITROGEN COMPOUND AND CORRESPONDING USE
SI21096B (sl) * 2001-10-09 2012-05-31 Encysive Pharmaceuticals Inc Derivati karboksilne kisline ki inhibirajo vezavo integrinov na njihove receptorje
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
PL374971A1 (en) * 2002-08-09 2005-11-14 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
KR100863667B1 (ko) 2002-09-11 2008-10-15 가부시끼가이샤 구레하 아민 화합물 및 그 용도
JP2007501844A (ja) * 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
WO2005014532A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US8227434B1 (en) 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
KR101149124B1 (ko) * 2004-03-10 2012-05-25 가부시끼가이샤 구레하 아민계 염기성 화합물과 그의 용도
US7615556B2 (en) * 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
US7601844B2 (en) * 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
BRPI0708331A2 (pt) 2006-02-27 2011-05-24 Elan Pharm Inc compostos de pirimidinil sulfonamida que inibem a adesão leucocitária mediada por vla-4
MX2010012234A (es) 2008-05-13 2011-03-03 Clarassance Inc Cc10 humana recombinante y composiciones del mismo para uso en el tratamiento de rinitis nasal.
TWI433838B (zh) * 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
MX2012004409A (es) 2009-10-15 2012-08-23 Clarassance Inc Proteina recombinante de humano cc10 para el tratamiento de la influenza.
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
AU2011328904A1 (en) * 2010-11-16 2013-06-06 Texas Heart Institute Agonists that enhance binding of integrin-expressing cells to integrin receptors
EP3116910A1 (en) 2014-03-13 2017-01-18 Prothena Biosciences Limited Combination treatment for multiple sclerosis
AU2015284263B2 (en) 2014-07-01 2021-02-25 7 Hills Pharma LLC Compositions and methods to improve adoptive cell therapies
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US20210393811A1 (en) * 2018-10-05 2021-12-23 Texas Heart Institute Imaging Agents and Methods of Use
JP7214882B2 (ja) 2018-10-30 2023-01-30 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
FI3873884T3 (fi) 2018-10-30 2025-02-24 Gilead Sciences Inc 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
CN119431230A (zh) 2019-08-14 2025-02-14 吉利德科学公司 用于抑制α4β7整合素的化合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372974A (en) * 1980-06-25 1983-02-08 New York University Anticonvulsive compositions and method of treating convulsive disorders
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
ZW6189A1 (en) * 1988-05-09 1990-05-09 Smithkline Beckman Corp Anti-aggregatory peptides
JPH0612525B2 (ja) 1989-10-12 1994-02-16 インターナショナル・ビシネス・マシーンズ・コーポレーション コンピュータプログラムの最適化方法
NZ235564A (en) 1989-10-13 1993-10-26 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical compositions
NZ235563A (en) * 1989-10-13 1993-04-28 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical composition
US5192746A (en) * 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
JPH06192273A (ja) * 1992-10-26 1994-07-12 Lederle Japan Ltd カルバペネム−３−カルボン酸エステル誘導体
DK0691953T3 (da) 1993-03-31 2000-09-04 Searle & Co 1-amidinophenyl-pyrrolidoner/piperidinoner som blodpladeaggreerende inhibiorer
JPH06298797A (ja) * 1993-04-12 1994-10-25 Fuji Photo Film Co Ltd ペプチド誘導体およびその用途
JP3190765B2 (ja) * 1993-05-13 2001-07-23 富士写真フイルム株式会社 ペプチド誘導体及びその用途
US5770573A (en) 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5821231A (en) 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
AU693143B2 (en) * 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5936065A (en) 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
US5811391A (en) * 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
JP2920741B2 (ja) * 1994-12-14 1999-07-19 参天製薬株式会社 新規１，３−ジアルキルウレア誘導体
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
ES2271971T3 (es) * 1996-07-25 2007-04-16 Biogen Idec Ma Inc. Inhibidores de la adhesion celular.
CN1265674A (zh) 1997-07-31 2000-09-06 伊兰药品公司 能抑制由vla－4介导的白细胞粘连的4－氨基苯基丙氨酸化合物
JP4555468B2 (ja) * 1997-10-31 2010-09-29 アベンテイス・フアルマ・リミテツド 置換アニリド
GB9723789D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds
HUP0100397A3 (en) * 1997-12-17 2002-10-28 Merck & Co Inc Tetrahydro- or octahydrobenzonaphtyridin and quinolin derivatives, pharmaceutical compositions thereof and process for their preparation
EP1079825B1 (en) 1998-04-16 2010-07-21 Encysive Pharmaceuticals, Inc Compounds that inhibit the binding of integrins to their receptors

Also Published As

Publication number Publication date
PL346220A1 (en) 2002-01-28
IL138973A0 (en) 2001-11-25
AU3748399A (en) 1999-11-01
CN1305473A (zh) 2001-07-25
EP1079825A2 (en) 2001-03-07
CA2328234A1 (en) 1999-10-21
HUP0101419A2 (hu) 2002-04-29
AU3563799A (en) 1999-11-01
PL343770A1 (en) 2001-09-10
HUP0101419A3 (en) 2002-08-28
CA2328990C (en) 2011-01-11
SK15602000A3 (sk) 2001-03-12
JP4949552B2 (ja) 2012-06-13
ID28658A (id) 2001-06-21
NO20005161D0 (no) 2000-10-13
CA2328990A1 (en) 1999-10-21
BR9909626A (pt) 2002-01-15
JP2002511463A (ja) 2002-04-16
US6096773A (en) 2000-08-01
NO20005161L (no) 2000-12-15
WO1999052493A2 (en) 1999-10-21
HUP0103752A2 (hu) 2002-07-29
NZ507534A (en) 2002-02-01
ES2345471T3 (es) 2010-09-23
CN1311676A (zh) 2001-09-05
ATE474573T1 (de) 2010-08-15
KR20010042704A (ko) 2001-05-25
EP1071680A1 (en) 2001-01-31
WO1999052898A1 (en) 1999-10-21
DE69942610D1 (de) 2010-09-02
TR200100141T2 (tr) 2001-06-21
SK15592000A3 (sk) 2001-12-03
JP2002511397A (ja) 2002-04-16
ES2308839T3 (es) 2008-12-01
ATE402170T1 (de) 2008-08-15
EP1079825A4 (en) 2003-03-05
US6262084B1 (en) 2001-07-17
HUP0103752A3 (en) 2002-11-28
EP1071680B1 (en) 2008-07-23
IL138972A0 (en) 2001-11-25
US6194448B1 (en) 2001-02-27
JP4753403B2 (ja) 2011-08-24
KR20010087125A (ko) 2001-09-15
CA2328234C (en) 2009-03-17
WO1999052493A3 (en) 2000-12-28
NO20005162D0 (no) 2000-10-13
EP1079825B1 (en) 2010-07-21
EP1071680A4 (en) 2003-03-05
BR9909625A (pt) 2002-01-15
DE69939165D1 (de) 2008-09-04
TR200100139T2 (tr) 2001-06-21

Similar Documents

Publication Publication Date Title
NO20005162L (no) Forbindelser som inhiberer bindingen av integriner til deres reseptorer
DK1176956T3 (da) Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer
NO20015394L (no) Karboksylsyrederivater som hemmer bindingen av integriner til deres reseptorer
NO20000265D0 (no) Kontrollert cytolyse av målceller, midler og sammensetninger som forårsaker cytolyse og forbindelser som kan anvendes for å fremstille midlene
NO20015419L (no) Propionsyrederivater som hemmer binding av integriner til deres reseptorer
DE69401204D1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
PT99435A (pt) Processo para a preparacao de derivados de amino-sulfonil-ureia e de composicoes farmaceuticas que os contem
NO992098L (no) Preparat med regulert avgivelse av aktiv forbindelse
NO20052753L (no) Kombinasjonsprodukter med karboksylsyrederivater som inhiberer bindingen av integriner til deres reseptorer, og andre terapeutiske forbindelser.
NO20002408L (no) 5-HT1F antagonister
WO2001010422A3 (en) Use of hepoxilins or hepoxilin analogs as antidiabetics, antiinframmatory agents
BR9811169A (pt) Proteìna-quinase que pertence à famìlia denominada civ1, ácido nucleico, vetor recombinante, processo de triagem de produtos fungicidas, e, utilização de um produto selecionado por este processo
MD943G2 (ro) Procedeu de obţinere a acizilor izotiocianatobenzoici
GT199800028A (es) Metodo de purificacion de 1, 3, 5-triisopropilbenceno.
NO950114L (no) Amylin-antagonister og agonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application